Literature DB >> 7944664

Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study.

L M Taylor1, R W Chitwood, R L Dalman, G Sexton, S H Goodnight, J M Porter.   

Abstract

BACKGROUND: Autoantibodies to phospholipid (aPL) have been associated with vascular thromboses in cerebral, coronary, and peripheral venous and arterial sites. To date, no large cross-sectional study has examined the incidence of occurrence of aPL in patients with peripheral arterial disease.
METHODS: A cross-sectional study was performed with patients admitted for vascular surgery procedures to treat peripheral arterial disease for 23 months between January 1, 1990 and November 1, 1991. Consecutive patients were evaluated for the presence of aPL. Medical records for each patient were reviewed in detail, and historic, operative, and postoperative parameters were tabulated for relationship to the presence of aPL.
RESULTS: Two hundred thirty-four patients underwent complete testing for aPL. All patients were receiving chronic aspirin therapy. This represented 86% of admissions. Antiphospholipid antibodies were detected in 60 patients (26%). No differences in age, sex, operation performed, or postoperative outcome were found between patients with and without aPL. However, patients with aPL were 1.8 times more likely to have undergone previous lower extremity (LE) vascular surgery than patients without aPL (95% confidence interval = 1.0 - 3.6, p = 0.047). Patients with aPL and previous LE vascular surgery were 5.6 times more likely to have had occlusion of that procedure than patients without aPL (95% confidence interval = 1.9 - 16.8, p = 0.03). The occluded previous LE procedures had a shorter duration of patency before occlusion in patients with aPL than in those without (mean duration of patency 17 months vs. 50 months, p < 0.003). Patients with occluded previous LE procedures and aPL were 4 times more likely to be female (95% C.I. = 1.4 - 11.3, p = 0.018).
CONCLUSIONS: The incidence of aPL in vascular surgery patients is substantial. Vascular surgery patients with aPL are more likely to have failure of previous LE bypass procedures and to be female and the bypass failure occurs significantly more rapidly than in patients without aPL. Based on these data, testing of vascular surgery patients for aPL and investigation of alternative antithrombotic treatment regimens in patients with aPL appears warranted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7944664      PMCID: PMC1234430          DOI: 10.1097/00000658-199410000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  19 in total

1.  THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS.

Authors:  E J BOWIE; J H THOMPSON; C A PASCUZZI; C A OWEN
Journal:  J Lab Clin Med       Date:  1963-09

2.  The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants.

Authors:  P Thiagarajan; V Pengo; S S Shapiro
Journal:  Blood       Date:  1986-10       Impact factor: 22.113

3.  Autogenous reversed vein bypass for lower extremity ischemia in patients with absent or inadequate greater saphenous vein.

Authors:  L M Taylor; J M Edwards; B Brant; E S Phinney; J M Porter
Journal:  Am J Surg       Date:  1987-05       Impact factor: 2.565

4.  Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure.

Authors:  D A Triplett; J T Brandt; D Kaczor; J Schaeffer
Journal:  Am J Clin Pathol       Date:  1983-06       Impact factor: 2.493

5.  Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal.

Authors:  R A Asherson; J K Chan; E N Harris; A E Gharavi; G R Hughes
Journal:  Ann Rheum Dis       Date:  1985-12       Impact factor: 19.103

6.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results.

Authors:  S Loizou; J D McCrea; A C Rudge; R Reynolds; C C Boyle; E N Harris
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

7.  Postoperative thrombotic complications in patients with lupus anticoagulant: increased risk after vascular procedures.

Authors:  S S Ahn; K Kalunian; M Rosove; W S Moore
Journal:  J Vasc Surg       Date:  1988-06       Impact factor: 4.268

8.  Fetal survival after prednisone suppression of maternal lupus-anticoagulant.

Authors:  W F Lubbe; W S Butler; S J Palmer; G C Liggins
Journal:  Lancet       Date:  1983-06-18       Impact factor: 79.321

9.  Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus.

Authors:  E N Harris; A E Gharavi; M L Boey; B M Patel; C G Mackworth-Young; S Loizou; G R Hughes
Journal:  Lancet       Date:  1983-11-26       Impact factor: 79.321

10.  Coronary artery bypass graft failure--an autoimmune phenomenon?

Authors:  K E Morton; T P Gavaghan; S A Krilis; G E Daggard; D W Baron; J B Hickie; C N Chesterman
Journal:  Lancet       Date:  1986-12-13       Impact factor: 79.321

View more
  7 in total

Review 1.  Association of anticardiolipin antibodies with vascular injury: possible mechanisms.

Authors:  Y S Haviv
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  The impact of inherited thrombophilia on surgery: a factor to consider before transplantation?

Authors:  Elias Kfoury; Ali Taher; Said Saghieh; Zaher K Otrock; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2008-05-31       Impact factor: 2.316

3.  Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.

Authors:  Victoria Ulrich; Eddy S Konaniah; Wan-Ru Lee; Sadiksha Khadka; Yu-Min Shen; Joachim Herz; Jane E Salmon; David Y Hui; Philip W Shaul; Chieko Mineo
Journal:  J Am Heart Assoc       Date:  2014-10-14       Impact factor: 5.501

Review 4.  Anticardiolipin antibodies and cardiovascular disease.

Authors:  K W Muir
Journal:  J R Soc Med       Date:  1995-08       Impact factor: 5.344

5.  Presence of antiphospholipid antibodies and thromboses.

Authors:  S S Nitecki
Journal:  Ann Surg       Date:  1995-08       Impact factor: 12.969

Review 6.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

Review 7.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.